Albumin Human 20% IV nfusion
Albumin Human 20%
Octapharma Pharmazeutika mbH,Germany
| Pack size | 50ml bot,100ml bot |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 3609.00,7218.00 AED |
Indications
Albumin Human 20% IV nfusion is used for:
Burns, Hypovolemia, Hypoalbuminemia, Hypoproteinaemia, Adult Respiratory Distress Syndrome, Nephrosis, Cardiopulmonary Bypass Surgery, Hemolytic Disease of the Newborn, Ovarian Hyperstimulation Syndrome, Acute hypovolaemic shock, Neonatal hyperbilirubinaemia
Adult Dose
Adult: Initially, 25 g of albumin, adjusted according to patient's response. Usual rates of infusion: Up to 1-2 ml/minute (20% solution).
Intravenous Hypoproteinaemia Adult: Up to 2 g/kg daily. Usual rates of infusion: Up to 1-2 ml/minute (20% solution).
Special Populations: Volume admin and rate of infusion must always be individualised according to situation and response. Usual rates of infusion are up to 1-2 ml/min (20% soln).
Child Dose
Child: Up to 1 g/kg, adjusted according to patient's response. Usual rates of infusion: Up to 1-2 ml/minute (20% solution).
Intravenous Neonatal hyperbilirubinaemia Child: 1 g/kg of albumin before exchange transfusion. Usual rates of infusion: Up to 1-2 ml/minute (20% solution).
Special Populations: Volume admin and rate of infusion must always be individualised according to situation and response. Usual rates of infusion are up to 1-2 ml/min (20% soln).
Renal Dose
Administration
Intravenous use only.
Contra Indications
Cardiac failure, severe anaemia, history of hypersensitivity, parenteral nutrition.
Precautions
Hypersensitivity or allergic reactions have been observed, and may in some cases progress to severe anaphylaxis. Epinephrine should be available immediately to treat any acute hypersensitivity reaction.
Hypervolemia: Use with caution in patients who are at risk of hypervolemia or hemodilution. Stop infusion if signs of cardiovascular overload occur.
Electrolyte imbalances have been observed. Monitor electrolyte status.
Ensure adequate substitution of other blood constituents. Monitor coagulation status and hematocrit.
Hypotension has been observed. Monitor hemodynamic performance.
Monitoring Parameters
Plasma and plasma substitutes are often used in very ill patients whose condition is unstable. Therefore, close monitoring is required and fluid and electrolyte therapy should be adjusted according to the patient’s condition at all times.
Monitor electrolyte status.
Monitor for signs of cardiac overload in injured or postoperative patients.
Monitor hemodynamic performance: this may include:
Arterial blood pressure and pulse rate
Central venous pressure
Pulmonary artery occlusion pressure
Urine output
Electrolytes
Hematocrit/hemoglobin.
Pregnancy-Lactation
Pregnancy
Pregnancy Category C.
Animal reproduction studies have not been performed with ALBUMIN (HUMAN) 20%. It is also not known whether ALBUMIN (HUMAN) 20% can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. ALBUMIN (HUMAN) 20% should be given to a pregnant woman only if necessary.
Labor and Delivery
It is also not known whether ALBUMIN (HUMAN) 20% can cause fetal harm when administered to a woman during labor or delivery of if it will affect reproductive capacity. ALBUMIN (HUMAN) 20% should be given during labor or delivery only if necessary.
Lactation
It is not known whether this drug is excreted in human milk. ALBUMIN (HUMAN) 20% should be given to nursing mothers only if necessary. Because many drugs are excreted in human milk, caution should be exercised when ALBUMIN (HUMAN) 20% is administered to a lactating woman.
Interactions
Albumin solution should not be mixed by protein hydrolysates or alcoholic solutions. Risk of atypical reactions to ACE inhibitors in patients undergoing therapeutic plasma exchange with albumin human replacement.
Adverse Effects
Side effects of Albumin Human 20% :
Allergic reactions, nausea, vomiting, increased salivation, fever and chills; vascular overload, haemodilution and pulmonary oedema.
Potentially Fatal: Anaphylactic shock.
Mechanism of Action
Human albumin increases intravascular oncotic pressure and causes movement of fluids from interstitial into intravascular space. Human albumin solutions are available in various concentrations. Solutions containing 5% human albumin are usually used in hypovolemic patients, whereas more concentrated 25% solutions are recommended in patients in whom fluid and sodium intake must be minimised e.g. patients with hypoproteinaemia or cerebral oedema or in paediatric patients.
Note
Albumin Human 20% IV nfusion manufactured by Octapharma Pharmazeutika mbH,Germany. Its generic name is Albumin Human 20%. Albumin Human 20% is availble in Bangladesh.
Farmaco BD drug index information on Albumin Human 20% IV nfusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.